CINCINNATI--(BUSINESS WIRE)--Feb. 26, 2015--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announces that it has
received the CE Mark for its new test for Streptococcus
pneumoniae (S. pneumo). TRU STREP PNEUMO™ is a rapid,
qualitative immunoassay for the detection of S. pneumo antigen in
urine and CSF and will be distributed in the EMEA regions by Meridian
Bioscience Europe and in additional international markets by the
Company’s global distribution network.
S. pneumo is the leading cause of community-acquired pneumonia
(CAP) with over 100,000,000 cases reported annually worldwide. It is
responsible for 30%-50% of adult CAP cases requiring hospitalization in
United States and Europe. S. pneumo is also associated with
invasive pneumococcal diseases (IPD) like meningitis and bacteremia,
which can have up to a 30% mortality rate.
Mike Shaughnessy, Executive Vice President and President of Meridian
Global Diagnostics, said “Strep pneumo is a common cause of pneumonia
that results in a variety of mild to severe disease outcomes. The new
TRU STREP PNEUMO™ test is an important tool that enables
laboratories to accurately detect the majority of CAP infections. TRU
STREP PNEUMO™, in combination with our already available TRU
LEGIONELLA®, enhances our portfolio of products that focus on
The TRU platform offers rapid, accurate results in a safe, closed system
format. In comparison to culture, the TRU STREP PNEUMO™ test
provides accurate, same day results that allow physicians to treat with
the appropriate antibiotic in a timely manner, improving patient
outcomes and decreasing healthcare costs.
Meridian is a fully integrated life science company that develops,
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions,
such as gastrointestinal, viral and respiratory infections. Meridian’s
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
health care. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and
technologies to hospitals, reference laboratories, research centers,
diagnostics manufacturers and biotech companies in more than 60
countries around the world. The Company’s shares are traded on the
NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Source: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
John A. Kraeutler, Chief Executive